X
[{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$85.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Pricing of $85.3 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Baillie Gifford","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Closing of $98.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Reports News Preclinical Data Suggesting Synergy Between STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Pricing of $126.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BioNova Pharmaceuticals","pharmaFlowCategory":"D","amount":"$204.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","amount":"$385.0 million","upfrontCash":"$40.0 million","newsHeadline":"Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$512.5 million","upfrontCash":"$90.0 million","newsHeadline":"Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,660.0 million","upfrontCash":"$60.0 million","newsHeadline":"Sutro Biopharma Achieves \u201cFirst in Human\u201d Milestone in Cytokine Derivatives Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","amount":"$157.5 million","upfrontCash":"$157.5 million","newsHeadline":"Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$390.0 million","upfrontCash":"$140.0 million","newsHeadline":"Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"$135.0 million","newsHeadline":"Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen and Sutro Biopharma announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFR\u03b1ME-O1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"VGXI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VGXI, Sutro Partner to Support Sutro's Clinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Sutro Biopharma
Filters
Companies By Therapeutic Area
Details:
The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.
Lead Product(s):
Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area: Oncology
Product Name: Luvelta
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Recipient:
VGXI
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
June 03, 2024
Details:
STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated in a phase 2/2 clinical trial for ovarian cancers in combination with Pegfilgrastim.
Lead Product(s):
Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area: Oncology
Product Name: Luvelta
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 30, 2024
Details:
Sutro intends to use the net proceeds of this offering to fund research, clinical, and development of STRO-002 (Luveltamab Tazevibulin) with Neulasta for treating patients with FOLR1-expressed Ovarian Neoplasms.
Lead Product(s):
Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area: Oncology
Product Name: STRO-002
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BofA Securities
Deal Size: $75.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
April 02, 2024
Details:
Under the licensing agreement, Ipsen has exclusive worldwide rights to develop and commercialize STRO-003, an ROR1 inhibitor currently undergoing clinical evaluation for the treatment of neoplasms.
Lead Product(s):
STRO-003
Therapeutic Area: Oncology
Product Name: STRO-003
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Ipsen
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
April 02, 2024
Details:
Under the agreement, Vaxcyte obtains exclusive rights to independently develop and manufacture cell-free extract, a key component of the company’s 24-valent pneumococcal conjugate vaccine (PCV) franchise which includes VAX-24 and VAX-31.
Lead Product(s):
24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: VAX-24
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Vaxcyte
Deal Size: $135.0 million
Upfront Cash: $135.0 million
Deal Type: Agreement
November 27, 2023
Details:
The financing will be used for the continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies, including VAX-24, a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine.
Lead Product(s):
24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: VAX-24
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Blackstone Life Sciences
Deal Size: $390.0 million
Upfront Cash: $140.0 million
Deal Type: Collaboration
June 26, 2023
Details:
STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated in a phase 1 clinical trial for ovarian and endometrial cancers. FDA has also granted the fast track designation for STRO-002.
Lead Product(s):
Luveltamab Tazevibulin
Therapeutic Area: Oncology
Product Name: STRO-002
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 09, 2023
Details:
Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs.
Lead Product(s):
STRO-002 ,Bevacizumab
Therapeutic Area: Oncology
Product Name: STRO-002
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 21, 2022
Details:
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease.
Lead Product(s):
24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: VAX-24
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Vaxcyte
Deal Size: $157.5 million
Upfront Cash: $157.5 million
Deal Type: Agreement
December 20, 2022
Details:
Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies.
Lead Product(s):
STRO-002
Therapeutic Area: Oncology
Product Name: STRO-002
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 03, 2022